A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgE<sub>Trap</sub>-Fc fusion protein, in participants with atopy or allergic diseases.
- DOI
- 10.1016/j.intimp.2026.117275
- Published
- 2026-08-13
- Container
- Int Immunopharmacol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.intimp.2026.117275,
title = {A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgE\<sub\>Trap\</sub\>-Fc fusion protein, in participants with atopy or allergic diseases.},
author = {Cho YS and Ye YM and Lee SY and Kim SH and Han TY and Ahn HH and Park YL and Lee YW and Ertle JM and Cho HJ and Sim S and Kim B and Lee J and Lee J and Kim SK and Lee JH and Jang MH and Park HS.},
year = {2026},
journal = {Int Immunopharmacol},
doi = {10.1016/j.intimp.2026.117275},
url = {https://doi.org/10.1016/j.intimp.2026.117275}
}RIS
TY - JOUR TI - A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgE<sub>Trap</sub>-Fc fusion protein, in participants with atopy or allergic diseases. AU - Cho YS AU - Ye YM AU - Lee SY AU - Kim SH AU - Han TY AU - Ahn HH AU - Park YL AU - Lee YW AU - Ertle JM AU - Cho HJ AU - Sim S AU - Kim B AU - Lee J AU - Lee J AU - Kim SK AU - Lee JH AU - Jang MH AU - Park HS. PY - 2026 JO - Int Immunopharmacol DO - 10.1016/j.intimp.2026.117275 UR - https://doi.org/10.1016/j.intimp.2026.117275 ER -
APA
YS, C., YM, Y., SY, L., SH, K., TY, H., HH, A., YL, P., YW, L., JM, E., HJ, C., S, S., B, K., J, L., J, L., SK, K., JH, L., MH, J., & HS., P. (2026). A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgE<sub>Trap</sub>-Fc fusion protein, in participants with atopy or allergic diseases.. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2026.117275
Source records
- europe-pmc · retrieved 2026-09-27T07:34:01.518Z